Yuhan eyes next Leclaza with R&D, open innovation after U.S. approval
Following the U.S. approval of lung treatment Leclaza, Korea’s first cancer drug to achieve the milestone, Yuhan Corporation is now seeking the next breakthrough with a renewed focus on research and development (R&D).
